SCHEMBL244916

SCHEMBL244916

O=C1[N]C(=O)c2c1cccc2[N+](=O)[O-]

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100A4 P26447 2/20 0.61
PTPRC P08575 1/20 0.56
MAPT P10636 2/20 0.54
KMT2A Q03164 2/20 0.54
RECQL P46063 1/20 0.54
MCL1 Q07820 1/20 0.54
RXFP1 Q9HBX9 1/20 0.54
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA7 P43166 1/20 0.51
CA9 Q16790 1/20 0.51
TDP1 Q9NUW8 3/20 0.48
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.44
CSNK2A2 P19784 1/20 0.44
CSNK2B P67870 1/20 0.44
CSNK2A1 P68400 1/20 0.44
CSNK2A3 Q8NEV1 1/20 0.44
GPR35 Q9HC97 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8979627 0.85 S100A4 (0.61) S100A4PTPRCMAPTKMT2ARECQL
SCHEMBL5157698 0.77 S100A4 (0.56) S100A4PTPRCMAPTKMT2ARECQL
SCHEMBL9257330 0.76 S100A4 (0.77) S100A4PTPRCMAPTKMT2ARECQL
SCHEMBL28651375 0.76 S100A4 (0.92) S100A4PTPRCMAPTKMT2ARECQL
SCHEMBL2347136 0.76 S100A4 (0.84) S100A4PTPRCMAPTKMT2ARECQL
SCHEMBL2599501 0.76 S100A4 (1.00) S100A4PTPRCMAPTKMT2ARECQL
SCHEMBL3039191 0.75 TDP1 (0.67) S100A4PTPRCMAPTKMT2ARECQL
SCHEMBL1303600 0.75 S100A4 (0.81) S100A4PTPRCMAPTKMT2ARECQL
SCHEMBL11317413 0.73 S100A4 (0.78) S100A4PTPRCMAPTKMT2ARECQL
SCHEMBL1559811 0.72 S100A4 (0.75) S100A4PTPRCMAPTKMT2ARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 751 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11807634-B2 Cyclopropyl dihydroquinoline sulfonamide compounds AMGEN INC. (US) 2023-11-07 US disclosed
US-20230234948-A1 CYCLOPROPYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS AMGEN INC. (US) 2023-07-27 US disclosed
US-20230227442-A1 HETEROALKYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS AMGEN INC. (US) 2023-07-20 US disclosed
EP-3897855-B1 KIF18A INHIBITORS AMGEN INC (US) 2023-06-07 EP disclosed
EP-4165024-A1 CYCLOBUTYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS Amgen Inc. (US) 2023-04-19 EP disclosed
EP-4165032-A1 HETEROALKYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS Amgen Inc. (US) 2023-04-19 EP disclosed
EP-4164748-A1 CYCLOPROPYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS Amgen Inc. (US) 2023-04-19 EP disclosed
CN-115697971-A Cyclobutyldihydroquinoline sulfonamide compound 美国安进公司 2023-02-03 CN disclosed
US-20220306604-A1 CYCLOBUTYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS AMGEN INC. (US) 2022-09-29 US disclosed
EP-4007753-A1 KIF18A INHIBITORS Amgen Inc. (US) 2022-06-08 EP disclosed
WO-1996022275-A1 METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES G.D. SEARLE & CO. (US) 1996-07-25 WO disclosed
EP-0715618-A1 HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1996-06-12 EP disclosed
EP-0656887-A1 HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1995-06-14 EP disclosed
WO-1995014653-A1 METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1995-06-01 WO disclosed
EP-0641333-A1 METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS. SEARLE & CO (US) 1995-03-08 EP disclosed
WO-1995006061-A1 RETROVIRAL PROTEASE INHIBITORS AND COMBINATIONS THEREOF G.D. SEARLE & CO. (US) 1995-03-02 WO disclosed
WO-1995006030-A1 HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1995-03-02 WO disclosed
WO-1994004492-A1 HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1994-03-03 WO disclosed
WO-1993023388-A1 METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1993-11-25 WO disclosed
EP-0301477-A2 Silver halide color photosensitive material and method of processing thereof Fuji Photo Film Co., Ltd. (JP) 1989-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227442-A1 HETEROALKYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS SCN7A, TRPV1, SCNN1A S100A4 1958/4885PTPRC 2378/4885MAPT 3487/4885
US-20230234948-A1 CYCLOPROPYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS TRPV1, SCN7A, TRPA1 S100A4 2191/4885PTPRC 2803/4885MAPT 1731/4885
US-11807634-B2 Cyclopropyl dihydroquinoline sulfonamide compounds TRPV1, SCN7A, TRPA1 S100A4 2631/4885PTPRC 2923/4885MAPT 1751/4885
US-20220306604-A1 CYCLOBUTYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS TRPV1, SCN7A, TRPA1 S100A4 2451/4885PTPRC 3734/4885MAPT 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.